Scleroderma News

September 22, 2020September 22, 2020

Scleroderma More Severe in People With Muscle Involvement, Study Finds

Scleroderma News

Muscular involvement is linked with more severe symptoms in people with scleroderma, affecting heart, lungs and the digestive system, a study from China reports. These patients are likely to have a ... Read more

September 17, 2020September 17, 2020

Rituximab Plus CellCept Durably Improves Lung Function in Refractory SSc-ILD, Study Suggests

Scleroderma News

Rituximab, in combination with CellCept (mycophenolate mofetil), reverses the decline in lung function in people with interstitial lung disease (ILD) associated with scleroderma (SSc) who did not respond to immunosuppressant ... Read more

September 15, 2020September 15, 2020

Study Describes 12 Cases of Lung Cancer in Women With Scleroderma

Scleroderma News

Detailed characteristics of 12 cases of lung cancer in people with scleroderma were described in a new study. Notably, all patients were women and most had interstitial lung disease (ILD). ... Read more

September 9, 2020September 9, 2020

Lenabasum Fails to Show Efficacy in Diffuse Cutaneous SSc, Phase 3 Trial Shows

Scleroderma News

Treatment with lenabasum failed to outperform a placebo when given as an add-on to standard immunosuppressants in adults with diffuse cutaneous scleroderma (dcSSc), top-line data from a Phase 3 trial ... Read more

September 2, 2020September 3, 2020

Same But Different Photo Contest Celebrates People With Rare Diseases

Scleroderma News

Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme “A ... Read more

August 31, 2020August 31, 2020

Enroll now for the Phase 2 Trial of CellCept Plus Esbriet for SSc-ILD

Scleroderma News

The Scleroderma Lung Study III (SLSIII), a Phase 2 clinical trial of oral CellCept (mycophenolate mofetil) alone or in combination with Esbriet (pirfenidone) in  scleroderma-associated interstitial lung disease (ILD) is enrolling patients. The trial (NCT03221257) ... Read more

August 24, 2020August 24, 2020

Scleroderma Patients Lacking Hallmark Autoantibodies Form Distinct Subset

Scleroderma News

People with scleroderma who lack disease-related autoantibodies show a clinically distinct profile, which includes younger age at disease onset, and differences in skin thickness and the proportion of patients with ... Read more

August 19, 2020August 19, 2020

EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US

Scleroderma News

The EveryLife Foundation for Rare Diseases has launched a scholarship fund in the U.S. to support individuals with rare disorders who are pursuing personal goals through training and education. The ... Read more

August 17, 2020August 18, 2020

Infections Needing Hospital Stay Costly for Scleroderma Patients in US

Scleroderma News

Pneumonia and sepsis are the most common serious infections among scleroderma patients needing hospitalization in the U.S., a study reports. Its findings also show that while the length of time these people ... Read more

August 12, 2020September 13, 2020

New Streaming Channel Showcases Rare Disease Films

COVID-19 News, Scleroderma News

When the COVID-19 pandemic forced the postponement of a rare disease film festival originally slated for May, its organizers set out to find a new way to bring the films ... Read more

August 10, 2020August 10, 2020

FLI1 Gene Variant Linked to Increased Scleroderma Risk, Greater Skin Thickness in Study

Scleroderma News

Long stretches of DNA repeats in the FLI1 gene — which gives instructions for a protein that controls the activity of genes — are linked to an increased risk for ... Read more

August 3, 2020August 3, 2020

1st Patients Dosed, Enrollment Open in Phase 2a Trial of CBD Therapy EHP-101 for dcSSc

Scleroderma News

The first patients have been dosed in a Phase 2a clinical trial of EHP-101, Emerald Health Pharmaceuticals‘ investigational cannabidiol-derived treatment for diffuse cutaneous systemic sclerosis (dcSSc), the company announced. So ... Read more

July 27, 2020July 27, 2020

Cell Therapy FCR001 to Enter Phase 1/2a Trial for Diffuse Cutaneous SSc

Scleroderma News

Talaris Therapeutics plans to initiate a Phase 1/2a trial to test its investigational cell therapy, FCR001, in people with diffuse cutaneous systemic sclerosis (dcSSc), the company has announced. The trial ... Read more

July 20, 2020July 20, 2020

Sleep Apnea Linked to High Blood Pressure in Lungs of Adults With Scleroderma

Scleroderma News

Obstructive sleep apnea (OSA) is associated with an increased risk of pulmonary hypertension in people with scleroderma, a study suggests. The study, “Impact of concomitant obstructive sleep apnea on pulmonary involvement and ... Read more

July 13, 2020July 13, 2020

ACR CRISS Score a Reliable Measure of Therapy Effectiveness in dcSSc Patients

Scleroderma News

The American College of Rheumatology Combined Response Index in diffuse cutaneous systemic sclerosis (ACR CRISS) appears to be a consistent and reliable measure of how these patients feel and function, according to data ... Read more